This is the authors' abstract. We don't add key points for this paper.
NanomedicineAhead of Print EditorialExosomes as a novel nanomedicine platform for personalized triple-negative breast cancer therapyAbhishesh Kumar Mehata, Niharika Gupta & Madaswamy S MuthuAbhishesh Kumar Mehata https://orcid.org/0000-0003-1392-5849Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, 221005, India, Niharika GuptaDepartment of Botany, Institute of Science (BHU), Varanasi, 221005, India & Madaswamy S Muthu *Author for correspondence: Tel.: +91 923 519 5928; E-mail Address: msmuthu.phe@iitbhu.ac.inhttps://orcid.org/0000-0001-5805-7921Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, 221005, IndiaPublished Online:17 May 2023https://doi.org/10.2217/nnm-2023-0074AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: exosomespersonalized nanomedicinetheranosticstriple-negative breast cancerPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Sun D, Zhuang X, Zhang S et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv. Drug Deliv. Rev. 65(3), 342–347 (2013).Crossref, Medline, CAS, Google Scholar2. Tang W, Xia M, Liao Y, Fang Y, Wen G, Zhong J. Exosomes in triple negative breast cancer: from bench to bedside. Cancer Lett. 527, 1–9 (2022). • Describes the roles of exosomes in triple-negative breast cancer.Crossref, Medline, CAS, Google Scholar3. Muthu MS, Agrawal P, Singh S. Theranostic nanomedicine of gold nanoclusters: an emerging platform for cancer diagnosis and therapy. Nanomedicine (Lond.) 11(4), 327–330 (2016).Link, CAS, Google Scholar4. Banerjee M, Rajeswari VD. Critical review on the different roles of exosomes in TNBC and exosomal-mediated delivery of microRNA/siRNA/lncRNA and drug targeting signalling pathways in triple-negative breast cancer. Molecules 28(4), 1–20 (2023). •• Complies with exosomal-mediated therapeutics delivery to triple-negative breast cancer.Crossref, Google Scholar5. Mehata AK, Viswanadh MK, Priya V, Muthu MS. Dendritic cell-targeted theranostic nanomedicine: advanced cancer nanotechnology for diagnosis and therapy. Nanomedicine (Lond.) 15(10), 947–949 (2020).Link, CAS, Google Scholar6. Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J. 6, 1–12 (2015).Crossref, Medline, Google Scholar7. Murar M, Albertazzi L, Pujals S. Advanced optical imaging-guided nanotheranostics towards personalized cancer drug delivery. Nanomaterials (Basel) 12(3), 1–17 (2022).Crossref, Google Scholar8. Weaver JW, Zhang J, Rojas J, Musich PR, Yao Z, Jiang Y. The application of exosomes in the treatment of triple-negative breast cancer. Front. Mol. Biosci. 9, 1022725 (2022).Crossref, Medline, CAS, Google Scholar9. Cully M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20(1), 6–7 (2021).Crossref, Medline, CAS, Google Scholar10. Gong C, Tian J, Wang Z et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J. Nanobiotechnol. 17(1), 93 (2019).Crossref, Medline, Google Scholar11. Yu M, Gai C, Li Z et al. Targeted exosome-encapsulated erastin-induced ferroptosis in triple-negative breast cancer cells. Cancer Sci. 110(10), 3173–3182 (2019). •• Presents iron-assisted apoptosis promoted in triple-negative breast cancer via exosomal delivery of erastin.Crossref, Medline, CAS, Google Scholar12. Piffoux M, Silva AKA, Wilhelm C, Gazeau F, Tareste D. Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems. ACS Nano 12(7), 6830–6842 (2018).Crossref, Medline, CAS, Google Scholar13. Delong RK, Risor A, Kanomata M et al. Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference. Nanomedicine (Lond.) 7(12), 1851–1862 (2012).Link, CAS, Google Scholar14. Mullis AS, Jacobson SJ, Narasimhan B. High-throughput synthesis and screening of rapidly degrading polyanhydride nanoparticles. ACS Comb. Sci. 22(4), 172–183 (2020).Crossref, Medline, CAS, Google Scholar15. Adir O, Poley M, Chen G et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv. Mater. 32(13), e1901989 (2020).Crossref, Medline, CAS, Google Scholar16. Dahlman JE, Kauffman KJ, Xing Y et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114(8), 2060–2065 (2017).Crossref, Medline, CAS, Google Scholar17. Majumder B, Baraneedharan U, Thiyagarajan S et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6, 6169 (2015).Crossref, Medline, CAS, Google Scholar18. Apaya MK, Shiau JY, Liao GS et al. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple-negative breast cancer. J. Exp. Clin. Cancer Res. 38(1), 187 (2019).Crossref, Medline, Google Scholar19. Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett. 352(1), 126–136 (2014).Crossref, Medline, CAS, Google Scholar20. Liu X, Tang I, Wainberg ZA, Meng H. Safety considerations of cancer nanomedicine–a key step toward translation. Small 16(36), e2000673 (2020). • Demonstrates the safety margin of nanomedicines for clinical translation.Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 14 March 2023 Accepted 30 March 2023 Published online 17 May 2023 Information© 2023 Future Medicine LtdKeywordsexosomespersonalized nanomedicinetheranosticstriple-negative breast cancerFinancial & competing interests disclosureThe authors are grateful to the Ministry of Human Resources and Development, New Delhi, for financial support in the form of a teaching assistantship conferred by the Indian Institute of Technology (Banaras Hindu University), Varanasi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mehata et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: